JP2016520057A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520057A5 JP2016520057A5 JP2016512418A JP2016512418A JP2016520057A5 JP 2016520057 A5 JP2016520057 A5 JP 2016520057A5 JP 2016512418 A JP2016512418 A JP 2016512418A JP 2016512418 A JP2016512418 A JP 2016512418A JP 2016520057 A5 JP2016520057 A5 JP 2016520057A5
- Authority
- JP
- Japan
- Prior art keywords
- mycobacteria
- use according
- cancer
- mtor inhibitor
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124302 mTOR inhibitor Drugs 0.000 claims 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 5
- 241000186359 Mycobacterium Species 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 241000187473 Mycobacterium aurum Species 0.000 claims 1
- 241001494992 Mycobacterium indicus pranii Species 0.000 claims 1
- 241000187918 Mycobacterium obuense Species 0.000 claims 1
- 241000187481 Mycobacterium phlei Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- -1 lidaforolimus Chemical compound 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1308325.8A GB201308325D0 (en) | 2013-05-09 | 2013-05-09 | Cancer Therapy |
| GB1308325.8 | 2013-05-09 | ||
| PCT/GB2014/051421 WO2014181121A1 (en) | 2013-05-09 | 2014-05-09 | Cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520057A JP2016520057A (ja) | 2016-07-11 |
| JP2016520057A5 true JP2016520057A5 (enExample) | 2017-06-15 |
Family
ID=48672024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512418A Pending JP2016520057A (ja) | 2013-05-09 | 2014-05-09 | 癌の治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160074494A1 (enExample) |
| EP (1) | EP2994148B8 (enExample) |
| JP (1) | JP2016520057A (enExample) |
| KR (1) | KR20160022803A (enExample) |
| CN (1) | CN105407901A (enExample) |
| AU (1) | AU2014264434A1 (enExample) |
| BR (1) | BR112015025719A2 (enExample) |
| CA (1) | CA2907841A1 (enExample) |
| DK (1) | DK2994148T3 (enExample) |
| ES (1) | ES2618050T3 (enExample) |
| GB (1) | GB201308325D0 (enExample) |
| HU (1) | HUE031783T2 (enExample) |
| MX (1) | MX2015014344A (enExample) |
| PL (1) | PL2994148T3 (enExample) |
| RU (1) | RU2015143106A (enExample) |
| SG (1) | SG11201507847UA (enExample) |
| SI (1) | SI2994148T1 (enExample) |
| WO (1) | WO2014181121A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| CA2990107A1 (en) * | 2015-06-24 | 2016-12-29 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
| KR101832892B1 (ko) * | 2015-08-24 | 2018-02-27 | 가톨릭대학교 산학협력단 | 면역억제제로 유발되는 미토콘드리아 질환 및 면역 질환의 예방 또는 치료를 위한 메트포민을 포함하는 조성물 |
| GB201601248D0 (en) * | 2016-01-22 | 2016-03-09 | Immodulon Therapeutics Ltd | Cancer therapy |
| GB201608806D0 (en) * | 2016-05-19 | 2016-07-06 | Immodulon Therapeutics Ltd | Method |
| WO2018112364A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating melanoma |
| WO2018112360A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating cancer |
| WO2019075452A1 (en) * | 2017-10-13 | 2019-04-18 | Evelo Biosciences, Inc. | IDENTIFICATION OF BACTERIA FOR CANCER THERAPY |
| CN109329204B (zh) * | 2018-10-12 | 2021-02-12 | 中国医学科学院北京协和医院 | 胰腺癌动物模型的构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2369542C (en) | 1999-04-23 | 2009-10-27 | Qlt Inc. | Immuno-adjuvant pdt treatment of metastatic tumors |
| US20020022032A1 (en) | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
| WO2006109300A1 (en) | 2005-04-14 | 2006-10-19 | Hadasit Medical Research Services & Development Ltd. | Pre-transplantation treatment of donor cells to control graft versus host disease (gvhd) in transplant recipients |
| WO2008110491A2 (en) * | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
| EP2085466A1 (en) * | 2008-01-29 | 2009-08-05 | AEterna Zentaris GmbH | Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof |
| SG177558A1 (en) * | 2009-07-08 | 2012-02-28 | Baltic Bio Ab | 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer |
| GB201120779D0 (en) * | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| US8617520B2 (en) * | 2012-02-15 | 2013-12-31 | Immodulon Therapeutics Limited | Cancer therapy |
-
2013
- 2013-05-09 GB GBGB1308325.8A patent/GB201308325D0/en not_active Ceased
-
2014
- 2014-05-09 SG SG11201507847UA patent/SG11201507847UA/en unknown
- 2014-05-09 RU RU2015143106A patent/RU2015143106A/ru not_active Application Discontinuation
- 2014-05-09 JP JP2016512418A patent/JP2016520057A/ja active Pending
- 2014-05-09 SI SI201430160A patent/SI2994148T1/sl unknown
- 2014-05-09 HU HUE14723864A patent/HUE031783T2/en unknown
- 2014-05-09 AU AU2014264434A patent/AU2014264434A1/en not_active Abandoned
- 2014-05-09 DK DK14723864.6T patent/DK2994148T3/en active
- 2014-05-09 US US14/785,579 patent/US20160074494A1/en not_active Abandoned
- 2014-05-09 CN CN201480020906.8A patent/CN105407901A/zh active Pending
- 2014-05-09 CA CA2907841A patent/CA2907841A1/en not_active Abandoned
- 2014-05-09 MX MX2015014344A patent/MX2015014344A/es unknown
- 2014-05-09 KR KR1020157028621A patent/KR20160022803A/ko not_active Withdrawn
- 2014-05-09 WO PCT/GB2014/051421 patent/WO2014181121A1/en not_active Ceased
- 2014-05-09 BR BR112015025719A patent/BR112015025719A2/pt not_active IP Right Cessation
- 2014-05-09 PL PL14723864T patent/PL2994148T3/pl unknown
- 2014-05-09 ES ES14723864.6T patent/ES2618050T3/es active Active
- 2014-05-09 EP EP14723864.6A patent/EP2994148B8/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520057A5 (enExample) | ||
| RU2015143106A (ru) | Терапия злокачественных опухолей | |
| JP2018531274A5 (ja) | 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物 | |
| JP2015518901A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| JP2016531927A5 (enExample) | ||
| JP2016538344A5 (enExample) | ||
| RU2016123370A (ru) | Ингибитор контрольных точек и цельноклеточная микробактерия для использования при лечении онкологического заболевания | |
| WO2015181641A3 (en) | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof | |
| JP2018516917A5 (enExample) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| JP2012513418A5 (enExample) | ||
| ZA201607488B (en) | Compounds for treating brain cancer | |
| EP3666273A3 (en) | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone | |
| JP2017527582A5 (enExample) | ||
| JP2016506413A5 (enExample) | ||
| JP2016522202A5 (enExample) | ||
| JP2019508403A5 (enExample) | ||
| CN113366008A (zh) | 一种cd73抑制剂，其制备方法和应用 | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| JP2019510075A5 (enExample) | ||
| JP2015518835A5 (enExample) | ||
| EA201301265A1 (ru) | Способ лечения солидных злокачественных опухолей, включая прогрессирующие или метастатические солидные злокачественные опухоли | |
| JP2017516827A5 (enExample) |